Daniel Estes, Ph.D.

General Partner

Dan is a General Partner on the Frazier Life Sciences team and has been involved with investing in and building many of Frazier’s biopharmaceutical portfolio companies over the past 11 years.

Dan joined Frazier Healthcare Partners in 2011 and focuses on investments in both development-stage and commercial-stage pharmaceutical companies. He has been a co-founder of and led Frazier’s investments in multiple companies including Arcutis (NASDAQ: ARQT), Lengo Therapeutics (acquired by Blueprint Medicines), Inipharm, and Radionetics Oncology. He has also led Frazier’s investments in Tarsus Pharmaceuticals (NASDAQ: TARS), Hummingbird Bioscience, and Cirius Therapeutics. He previously served on the boards of Semnur Pharmaceuticals (acquired by Scilex) and Sierra Oncology (acquired by GSK).

Dan has also been involved in Frazier’s investments in Acerta Pharma BV (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Ignyta (acquired by Roche), Iovance (NASDAQ: IOVA), Vaxcyte (NADAQ: PCVX), Translate Bio (acquired by Sanofi), and PreCision Dermatology (acquired by Valeant).

Prior to joining Frazier, Dan was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised leading global pharmaceutical and biotechnology companies on R&D strategy and business development strategy. He received his Ph.D. in Biomedical Engineering from the University of Michigan and holds a B.S. in Electrical Engineering from Stanford University, where he is a member of Tau Beta Pi.

Menlo Park

Stanford University (B.S.)
University of Michigan (Ph.D.)

Year Joined